WallStSmart

Abbott Laboratories (ABT)vsENvue Medical Inc. (FEED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 2069318% more annual revenue ($45.13B vs $2.18M). ABT leads profitability with a 13.9% profit margin vs 0.0%. ABT earns a higher WallStSmart Score of 54/100 (C-).

ABT

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

FEED

Avoid

30

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 2/9Altman Z: -1.85
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-34.4%)

Margin of Safety

-34.4%

Fair Value

$70.96

Current Price

$95.40

$24.44 premium

UndervaluedFair: $70.96Overvalued

Intrinsic value data unavailable for FEED.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$163.94B9/10

Large-cap with strong market position

FEED2 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Areas to Watch

ABT2 concerns · Avg: 3.0/10
P/E RatioValuation
26.4x4/10

Moderate valuation

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

FEED4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$3.14M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.40 suggests the stock is reasonably priced for its growth.

Bull Case : FEED

The strongest argument for FEED centers on Price/Book, Debt/Equity.

Bear Case : ABT

The primary concerns for ABT are P/E Ratio, EPS Growth.

Bear Case : FEED

The primary concerns for FEED are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

FEED carries more volatility with a beta of 1.50 — expect wider price swings.

ABT is growing revenue faster at 7.8% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (54/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

ENvue Medical Inc.

HEALTHCARE · MEDICAL DEVICES · USA

ENvue Medical Inc. (FEED) is an innovative healthcare technology company dedicated to enhancing patient care management through cutting-edge medical devices and integrated software solutions. By leveraging advanced technology, ENvue aims to streamline recovery processes and optimize health outcomes across diverse clinical environments. With a strong pipeline of products and strategic partnerships, the company is well-equipped to capitalize on the expanding opportunities in the healthcare sector, making it an attractive investment prospect for institutional investors interested in the evolution of medical devices and digital health innovations.

Want to dig deeper into these stocks?